Navigation Links
Pharmaceutical & Healthcare Annual Deals Analysis 2012
Date:3/14/2012

NEW YORK, March 14, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical & Healthcare Annual Deals Analysis 2012

http://www.reportlinker.com/p0453489/Pharmaceutical--Healthcare-Annual-Deals-Analysis-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceutical & Healthcare Annual Deals Analysis 2012

Summary GlobalData's "Pharmaceutical & Healthcare Annual Deals Analysis 2012" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on Partnerships, Licensing Agreements, M&As, Equity/Debt Offerings, Private Equity and Venture Financing transactions registered in the pharmaceutical and healthcare industry in 2011. The report presents detailed comparative data on the number of deals and their value in the past five years categorized into deal types, segments, and geographies. Additionally, the report provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharma eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena. - Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.- Analysis of partnership and licensing deals based on clinical stage of development of products.-

Summary

of the pharmaceutical deals globally in the last five years- Information on the top deals happened in the pharmaceutical industry.- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.- Find out the major deal performing segments for investments in your industry.- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.- Identify companies that are aggressively looking to raise capital in the market- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.- Identify growth segments and opportunities in each region within the industry.- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.1 Table of contents1 Table of contents 21.1 List of Tables 41.2 List of Figures 72 Pharmaceutical & Healthcare, Global, Deals Summary 92.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2011 92.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2011 by Quarter 112.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, 2011 132.3 Pharmaceuticals & Healthcare, Global, Top Deals, 2011 142.4 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2011 152.4.1 Medco Health Receives Shareholders' Approval For Its Acquisition By Express Scripts 152.4.2 Takeda Pharmaceutical Completes Acquisition Of Nycomed International For $13.7 Billion 152.4.3 Gilead Sciences Completes Acquisition Of Pharmasset For $11.2 Billion 162.4.4 Sanofi Completes Public Offering Of Notes For $7 Billion 162.4.5 Teva Completes Acquisition Of Cephalon For $6.8 Billion 162.4.6 DuPont Completes Acquisition Of Danisco 172.4.7 Amgen Completes Public Offering Of Senior Notes For $6 Billion 172.4.8 HCA Completes Public Offering Of Senior Secured Notes For $5 Billion 172.4.9 Teva Pharmaceutical Completes Public Offering Of Senior Notes For $5 Billion 172.4.10 Johnson & Johnson Completes Public Offering Of Notes For $4.4 Billion 183 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2011 194 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 204.1 Pharmaceuticals & Healthcare, Global, M&A, 2011 204.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2011 by Quarter 214.1.2 Top M&A Deals in 2011 224.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2011 234.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2011 244.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2011 by Quarter 254.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2011 264.2.3 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2011 284.2.4 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2011 304.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2011 324.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2011 334.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2011 by Quarter 344.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2011 354.3.3 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2011 374.3.4 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2011 394.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2011 404.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2011 by Quarter 414.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2011 434.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2011 444.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2011 454.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), 2011 464.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2011 474.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2011 504.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2011 by Quarter 514.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2011 524.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2011 534.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2011 544.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, Number Of Deals and Deal Value (US$ m), 2011 554.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2011 564.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2011 594.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2011 by Quarter 604.6.2 Top Private Equity Deals in 2011 614.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2011 624.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2011 634.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2011 by Quarter 644.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2011 654.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2011 664.7.4 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 674.7.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2011 684.7.6 Top Venture Financing Deals in 2011 695 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 705.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2011 705.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2011 by Quarter 725.1.2 Oncology - Deals of the Year 735.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2011 755.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2011 by Quarter 775.2.2 Central Nervous System - Deals of the Year 785.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2011 805.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2011 by Quarter 815.3.2 Infectious Disease - Deals of the Year 825.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2011 845.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2011 by Quarter 855.4.2 Immunology - Deals of the Year 865.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2011 885.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2011 by Quarter 895.5.2 Cardiovascular - Deals of the Year 905.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2011 915.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2011 by Quarter 925.6.2 Metabolic Disorders - Deals of the Year 935.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2011 955.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2011 by Quarter 975.7.2 Gastrointestinal - Deals of the Year 986 Pharmaceuticals & Healthcare, Deal Summary, By Geography 1006.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2011 1006.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2011 by Quarter 1016.1.2 North America – Deals of the Year 1026.2 Pharmaceuticals & Healthcare, European Region Deals, 2011 1046.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2011 by Quarter 1066.2.2 Europe – Deals of the Year 1076.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2011 1096.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2011 by Quarter 1106.3.2 Asia-Pacific – Deals of the Year 1116.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2011 1126.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2011 by Quarter 1136.4.2 Rest of the World – Deals of the Year 1147 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 1157.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2011 1157.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2011 1168 Further Information 1188.1 Methodology 1188.2 About GlobalData 1188.3 Contact Us 1198.4 Disclosure information 1198.5 Disclaimer 119

List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 10Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2011-Q4 2011 12Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2011 13Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2011 14Table 5: Pharmaceuticals & Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (US$ m), 2011 19Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 20Table 7: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 21Table 8: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2011 22Table 9: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2011 23Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 24Table 11: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 25Table 12: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 26Table 13 Pharmaceuticals & Healthcare, Global, Top IPOs, 2011 27Table 14: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 28Table 15: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2011 29Table 16: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 30Table 17: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2011 31Table 18: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 32Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 33Table 20: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 34Table 21: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 35Table 22: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2011 36Table 23: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 37Table 24: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2011 38Table 25: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2011 39Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2007 - 2011 40Table 27: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2011–Q4 2011 41Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2011 43Table 29: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2011 44Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2011 45Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2011 46Table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2011 47Table 33: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2011 48Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2011 48Table 35: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2011 49Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 50Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011–Q4 2011 51Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2011 52Table 39: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2011 53Table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2011 54Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, 2011 55Table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2011 56Table 43: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2011 57Table 44: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2011 57Table 45: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2011 58Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 59Table 47: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 60Table 48: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2011 61Table 49: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 62Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 63Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 64Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2011 65Table 53: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 66Table 54: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2011 67Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2011 68Table 56: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2011 69Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 71Table 58: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 72Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 76Table 60: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 78Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 80Table 62: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 81Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 84Table 64: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 85Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 88Table 66: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 89Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 91Table 68: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 92Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 96Table 70: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 97Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 100Table 72: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2011–Q4 2011 102Table 73: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 105Table 74: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2011-Q4 2011 107Table 75: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 109Table 76: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2011-Q4 2011 110Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2007 - 2011 112Table 78: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2011–Q4 2011 113Table 79: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2011 115Table 80: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2011 117

List of Figures

Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2007- 2011 9Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2011-Q4 2011 11Figure 3: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%), 2011 13Figure 4 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2007 - 2011 20Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 21Figure 6: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2011 23Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2007 - 2011 24Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 25Figure 9: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2007 - 2011 26Figure 10: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2007 - 2011 28Figure 11: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2007 - 2011 30Figure 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2011 32Figure 13: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2007 - 2011 33Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 34Figure 15: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2007 - 2011 35Figure 16: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2007 - 2011 37Figure 17: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2011 39Figure 18: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2007 - 2011 40Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 41Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2011 42Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2011 43Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2011 44Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2011 45Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2011 46Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2011 47Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2007 - 2011 50Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 51Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2011 52Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2011 53Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2011 54Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, 2011 55Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2011 56Figure 33: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2007 - 2011 59Figure 34: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 60Figure 35: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2011 62Figure 36: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2007 - 2011 63Figure 37: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 64Figure 38: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), 2011 65Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2011 66Figure 40: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2011 68Figure 41: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2007 - 2011 70Figure 42: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 72Figure 43: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2011, 2007 - 2011 75Figure 44: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 77Figure 45: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2007 - 2011 80Figure 46: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2011-Q4 2011 81Figure 47: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2007 - 2011 84Figure 48: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 85Figure 49: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2007 - 2011 88Figure 50: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 89Figure 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2007 - 2011 91Figure 52: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 92Figure 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2007 - 2011 95Figure 54: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2011-Q4 2011 97Figure 55: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2007 - 2011 100Figure 56: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2011–Q4 2011 101Figure 57: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2007 - 2011 104Figure 58: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2011–Q4 2011 106Figure 59: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2007 - 2011 109Figure 60: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2011–Q4 2011 110Figure 61: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2007 - 2011 112Figure 62: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2011–Q4 2011 113Figure 63: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2011 115Figure 64: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2011 116

To order this report:Pharmaceutical Industry: Pharmaceutical & Healthcare Annual Deals Analysis 2012

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Sihuan Pharmaceutical Achieves Important R&D Breakthrough
2. Omnicell to Exhibit at Dubai International Pharmaceuticals and Technologies Conference and Exhibition
3. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
4. Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference
5. S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
6. Questcor Pharmaceuticals to Present at the 24th Annual ROTH Conference on March 12, 2012
7. Patented Protection Against Counterfeit Pharmaceuticals and Retail Fraud. ICAP Patent Brokerage Announces for Auction a Patented System for Verification of Purchase and Product Legality
8. Gamma Pharmaceuticals, Inc. Announces Key Appointment in Sales and Marketing
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Full Year 2011 Results
10. The Outlook for Pharmaceuticals in Western Europe
11. ASLAN Pharmaceuticals Selects PharmaNet/i3 as Strategic Partner For Oncology Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 A ... which will be held at Victoria Park Plaza in ... an informative seminar on technology and future advances for late ... led by Lorna Graham , associate director of project ... to keep up with new regulations and standards in late ...
(Date:2/10/2016)... Puerto Rico Healthcare and Life Sciences Report 2016 ... Report 2016 . --> Focus Reports releases ... Sciences Report 2016 . pharmaceuticals , or ... world for pharma manufacturing, a territory with significantly improved capabilities ... per square mile than anywhere else on the planet. ...
(Date:2/10/2016)... , Feb. 10, 2016 Convergence ... confluence of various technologies that results in ... unavailable. These opportunities create a cyclical system ... turn, drives the development of new technologies. ... characterized by technology convergences, which are constantly ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... medical dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and ... Indicator sensor for resistance cord exercise and therapy, introduces its new microFET Digital ...
(Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and ... in order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige ... Clio, only 15 miles away from Flint. , “We have deep roots in the ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
Breaking Medicine News(10 mins):